SNOA vs BMRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SNOA Captures Institutional Edge (2โ1 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sonoma Pharmaceuticals, Inc. Common Stock (SNOA) driven by superior Valuation, Growth & Margin while BMRA counters with relative strength in Momentum & Technical. Fundamentally, SNOA trades at 46.1x Forward P/E with -3.3% operating margin (+28.0% YoY revenue) versus BMRA at N/M Forward P/E and -125.2% operating margin (-8.3% YoY). In options structure, SNOA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BMRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SNOA Revenue | BMRA Revenue | SNOA Op. Margin | BMRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $20M | $10M | -59.3% | -46.4% | BMRA |
| FY2020 | $20M | $10M | -41.2% | -41.0% | BMRA |
| FY2021 | $20M | $10M | -18.5% | -104.2% | SNOA |
| FY2022 | $10M | $20M | -46.6% | -24.0% | BMRA |
| FY2023 | $10M | $10M | -34.4% | -135.3% | SNOA |
| FY2024 | $10M | $10M | -36.9% | -117.6% | SNOA |
| FY2025 | $10M | $10M | -26.0% | -96.7% | SNOA |
| FY2026 | $20M | $0M | -12.6% | -119.5% | SNOA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SNOA | BMRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $5.6M | $6.0M | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | 46.1x | N/M | Lower Multiple | SNOA |
| Forward P/E Ratio Valuation | 46.1x | N/M | Lower Multiple | SNOA |
| Revenue Growth (YoY) Growth | +28.0% | -8.3% | Higher Growth | SNOA |
| Operating Margin (TTM) Profitability | -3.3% | -125.2% | Higher Margin | SNOA |
| Net Profit Margin Profitability | -7.6% | -115.5% | Higher Margin | SNOA |
| Return on Equity (ROE) Capital Efficiency | -34.5% | -113.8% | Higher ROE | SNOA |
| 52-Week Range Position Momentum | 1% ($1โ$4) | 4% ($1โ$3) | Stronger Trend | BMRA |
| Beta / 30D Volatility Risk Regime | 1.39ฮฒ ยท 78% Vol | 0.67ฮฒ ยท 62% Vol | Lower Realized Risk | BMRA |
| Unified Institutional Score Composite Signal | 51.6 / 100 (HOLD) | 44.5 / 100 (HOLD) | Higher Composite | SNOA |